A. Chan Et Al. , "Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial," CLINICAL BREAST CANCER , vol.21, no.1, pp.80-98, 2021
Chan, A. Et Al. 2021. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. CLINICAL BREAST CANCER , vol.21, no.1 , 80-98.
Chan, A., Moy, B., Mansi, J., Ejlertsen, B., Holmes, F. A., Chia, S., ... Iwata, H.(2021). Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. CLINICAL BREAST CANCER , vol.21, no.1, 80-98.
Chan, Arlene Et Al. "Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial," CLINICAL BREAST CANCER , vol.21, no.1, 80-98, 2021
Chan, Arlene Et Al. "Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial." CLINICAL BREAST CANCER , vol.21, no.1, pp.80-98, 2021
Chan, A. Et Al. (2021) . "Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial." CLINICAL BREAST CANCER , vol.21, no.1, pp.80-98.
@article{article, author={Arlene Chan Et Al. }, title={Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial}, journal={CLINICAL BREAST CANCER}, year=2021, pages={80-98} }